Findings described above showed that in CCA and PDAC preclinical models, CDK4/6 inhibitors used as single agents can induce cell cycle arrest and mostly senescence and to a much lesser extent, programmed cell death (apoptosis). The gene discussed is CDK4; the disease is cholangiocarcinoma.